Form 4: Arcutis Biotherapeutics Executive Sells Shares to Cover Tax Obligations

Larry Todd Edwards, an executive at Arcutis Biotherapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On February 3, 2025, Larry Todd Edwards, Executive Vice President and Chief Commercial Officer of Arcutis Biotherapeutics, sold 2,173 shares of common stock at a weighted average price of $12.7 per share.
• The sale was to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted on January 12, 2024.
• 25% of the RSUs vest annually beginning on February 1, 2025, subject to continued service to the Issuer.
• Following the transaction, Edwards beneficially owns 135,555 shares of Arcutis Biotherapeutics.
• An adjustment was made to reflect the acquisition of 1,093 shares under the Company's Employee Stock Purchase Plan on November 30, 2024, which were erroneously reported in a previous filing.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction to cover tax obligations, and there's no indication of a change in the executive's confidence in the company.

Industry Context

Executive stock sales are a common occurrence and are often related to tax obligations or portfolio diversification. The sale itself doesn't necessarily indicate a negative outlook for the company.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact on other stakeholders.

Key Dates

Keywords

Arcutis Biotherapeutics, Larry Todd Edwards, Form 4, share sale, restricted stock units, tax withholding, beneficial ownership, ARQT, Employee Stock Purchase Plan